8 results about "Peramivir" patented technology

The present disclosure relates to compositions and methods for treating viral infections. Compositions and methods for treating viral infections include conjugates comprising a viral neuraminidase inhibitor (e.g., zanamivir, peramivir, or an analog thereof) linked to an Fc monomer, an Fc domain, and an Fc binding peptide, albumin, or an albumin binding peptide. In particular, the conjugates are useful in the treatment of viral infections (e.g., influenza virus infections).

The invention relates to an amino-acid ester prodrug of peramivir, which has the following structural formula: in the formula, R is L-valine, D-valine and L-isoleucine taking 2, 3-butanediol as a connecting arm, and L-isoleucine, L-alanine, L-valine or D-valine taking 2-methyl-1, 3-propylene glycol as a connecting arm. Mouse in-vivo pharmacokinetic verification shows that the amino-acid ester prodrug of the peramivir has remarkably higher absolute bioavailability and is suitable for being prepared into an oral administration preparation.

Compositions and methods for the treatment of viral infections include conjugates containing inhibitors of viral neuraminidase (e.g., zanamivir, peramivir, or analogs thereof) linked to an Fc monomer, an Fc domain, and Fc-binding peptide, an albumin protein, or albumin-binding peptide. In particular, conjugates can be used in the treatment of viral infections (e.g., influenza viral infections).

The invention discloses an application of a Wevir drug in preparation of a drug for resisting canine distemper virus. It is found that 20-100 [mu] M of pirentamivir and ombitasvir have no obvious toxic effect on MDCK cells, and 20 [mu] M of pirentamivir and ombitasvir can significantly inhibit canine distemper virus proliferation, which indicates that pirentamivir and ombitasvir can become a new choice for preparation of anti-canine distemper virus drugs. The pirentamivir and ombitasvir pharmaceutical composition is a new use of an old medicine, the pharmacokinetic data of pirentamivir and ombitasvir which are sold on the market are detailed, the safety is reliable, the development of the new use can be quickly performed for second-stage clinical evaluation, the research and development period is shortened, the development cost is saved, and resources can be utilized to the maximum extent.

Compositions and methods for treating viral infections include conjugates containing a viral neuraminidase inhibitor (e.g., zanamivir, peramivir, or analogs thereof) linked to an Fc monomer, Fc domain, and Fc binding peptide, albumin, or albumin binding peptide. In particular, the conjugates can be used to treat viral infections (e.g., influenza virus infections).

This invention relates to the field of pharmaceutical analysis technology, and provides a method for detecting enantiomers in peramivir sodium chloride injection. The method employs high-performance liquid chromatography (HPLC), with the following chromatographic conditions: a column packed with α1-acidic glycoprotein-bonded silica gel; a mobile phase consisting of a mixture of 0.02 mol / L ammonium dihydrogen phosphate solution and 0.02 mol / L diammonium hydrogen phosphate solution at a volume ratio of 45:55 to 55:45; a detection wavelength of 205 nm; a flow rate of 0.25 to 0.35 mL / min; and a column temperature of 18 to 22 °C. Before detection, a test solution, a reference solution, and a system suitability solution are prepared, and each solution is accurately injected into the HPLC system. The chromatograms are recorded, and the enantiomer content is calculated. The advantages of this invention are: simple operation, no sodium chloride interference, and accurate quantitative detection of enantiomers in peramivir sodium chloride injection.

Compositions and methods for the treatment of viral infections include conjugates containing inhibitors of viral neuraminidase (e.g., zanamivir, peramivir, or analogs thereof) linked to an Fc monomer, an Fc domain, and Fc-binding peptide, an albumin protein, or albumin-binding peptide. In particular, conjugates can be used in the treatment of viral infections (e.g., influenza viral infections).

The invention relates to the field of food detection, in particular to an analysis and detection method for antiviral drug residues in eggs, which comprises the following steps: S1, sample pretreatment: 1.1, sample preparation: shelling eggs, homogenizing, and storing at 4 DEG C; 1.2, extracting: weighing a homogenate sample, extracting twice by using 90% acetonitrile-1% formic acid solution, and merging supernate; 1.3, purifying and redissolving: purifying the supernate through an EMR-Lipid solid-phase extraction column, collecting eluent, blowing the eluent to be nearly dry at 40 DEG C by nitrogen, redissolving by using a formic acid-methanol solution, and filtering to obtain a matrix extracting solution; s2, preparing a standard solution; s3, instrument detection: performing chromatography-tandem mass spectrometry detection; s4, quantitative analysis: calculating the residual quantity of the eight antiviral drugs in the eggs according to the quantitative ion peak area by adopting a matrix matching standard curve external standard method. The precise detection of eight viruses, namely nevirapine, peramivir, famciclovir, rimantadine, amantadine, oseltamivir, imiquimod and memantine, is realized.